Carla Torre1, José Guerreiro2, Sofia de Oliveira Martins3, João Filipe Raposo4, Ana Paula Martins3, Hubert Leufkens5. 1. Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal. Electronic address: carla.torre@anf.pt. 2. Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal. 3. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal; Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal. 4. Faculty of Medical Sciences, New University of Lisbon, Lisboa, Portugal; Portuguese Diabetes Association (APDP), Lisboa, Portugal. 5. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Abstract
AIMS: To compare the temporal trends in the consumption patterns of glucose lowering drugs (GLD) between Portugal and the Netherlands from 2004 to 2013 and to examine possible reasons behind the cross-national variation found. METHODS: All GLD (ATC pharmacological subgroup A10B) were selected for analysis. Consumption data were obtained for the 10-year period. Portuguese and Dutch drug estimates were obtained from nationwide databases. RESULTS: The consumption of GLD increased in Portugal from 52.9 defined daily dose per 1000 inhabitants per day (DHD) in 2004 to 70.0 DHD in 2013 and in the Netherlands from 44.9 DHD in 2004 to 50.7 DHD in 2013. In Portugal, the use of fixed-dose combinations, especially with dipeptidyl peptidase-4 inhibitors (DPP-4) increased remarkably and in 2013 represented almost a quarter of total GLD consumption. In the Netherlands, the use of combinations was residual. CONCLUSIONS: The consumption of GLD rose over the 10-year period in both countries. However, Portuguese overall consumption and costs of GLD were higher. The differentially rapid uptake of DPP-4 inhibitors in Portugal was the main driver of the cost difference.
AIMS: To compare the temporal trends in the consumption patterns of glucose lowering drugs (GLD) between Portugal and the Netherlands from 2004 to 2013 and to examine possible reasons behind the cross-national variation found. METHODS: All GLD (ATC pharmacological subgroup A10B) were selected for analysis. Consumption data were obtained for the 10-year period. Portuguese and Dutch drug estimates were obtained from nationwide databases. RESULTS: The consumption of GLD increased in Portugal from 52.9 defined daily dose per 1000 inhabitants per day (DHD) in 2004 to 70.0 DHD in 2013 and in the Netherlands from 44.9 DHD in 2004 to 50.7 DHD in 2013. In Portugal, the use of fixed-dose combinations, especially with dipeptidyl peptidase-4 inhibitors (DPP-4) increased remarkably and in 2013 represented almost a quarter of total GLD consumption. In the Netherlands, the use of combinations was residual. CONCLUSIONS: The consumption of GLD rose over the 10-year period in both countries. However, Portuguese overall consumption and costs of GLD were higher. The differentially rapid uptake of DPP-4 inhibitors in Portugal was the main driver of the cost difference.
Authors: J Moon; S S Kumar; G G Graham; M T Baysari; K M Williams; W Chen; A Viardot; J R Greenfield; R O Day Journal: Eur J Clin Pharmacol Date: 2016-08-27 Impact factor: 2.953
Authors: Peter Eibich; Amelia Green; Andrew T Hattersley; Christopher Jennison; Mike Lonergan; Ewan R Pearson; Alastair M Gray Journal: Diabetes Ther Date: 2017-09-06 Impact factor: 2.945
Authors: Suzete Costa; Maria Rute Horta; Rita Santos; Zilda Mendes; Isabel Jacinto; José Guerreiro; Maria Cary; Ana Miranda; Dennis K Helling; Ana Paula Martins Journal: J Pharm Policy Pract Date: 2019-03-21
Authors: Kate N O Neill; Kathleen E Bennett; Sheena M Mc Hugh; Anthony P Fitzgerald; Patricia M Kearney Journal: BMJ Open Date: 2020-10-10 Impact factor: 2.692
Authors: Carla Torre; José Guerreiro; Patrícia Longo; João Filipe Raposo; Hubert Leufkens; Ana Paula Martins Journal: Patient Prefer Adherence Date: 2018-08-17 Impact factor: 2.711